文献速递其他结缔组织病

原发性干燥综合征患者流感疫苗接种后的免疫应答研究

Immune responses after influenza vaccination in patients of primary Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究纳入17例原发性干燥综合征(pSS)患者和16例健康对照,评估流感疫苗接种后的免疫应答变化及安全性。结果显示pSS患者接种后疫苗特异性IgG水平高于健康对照(P=0.001),Th1和Th17细胞比例显著升高(P<0.05),Tfh细胞无显著变化(P=0.1748),疾病表现和实验室参数无显著改变,未观察到疫苗接种相关不良事件增加。结论提示流感疫苗可用于pSS患者。

要点

  • pSS患者接种流感疫苗后疫苗特异性IgG水平显著高于健康对照(P=0.001)。
  • pSS患者接种后Th1和Th17细胞比例显著升高(P<0.05),Tfh细胞无显著变化(P=0.1748)。
  • 接种后疾病表现和实验室参数无显著改变,未见疫苗接种相关不良事件增加。

核心结论

  • 研究提示流感疫苗可应用于pSS患者,并应提高风湿病学界及相关医护人员对疫苗接种的意识。

研究设计与样本

  • 研究纳入17例pSS患者和16例健康对照,采用流式细胞术分析外周单个核细胞,ELISA检测疫苗特异性抗体,并监测临床特征和血清学应答。

主要发现

  • 健康对照接种后Tfh细胞百分比显著升高(P=0.0005),pSS患者Tfh水平无显著差异(P=0.1748)。
  • pSS患者和健康对照接种后Th2细胞比例均显著下降(P<0.05)。
  • pSS患者接种后Th1和Th17细胞百分比显著升高(P<0.05),健康对照无显著差异(P>0.05),但健康对照Th1细胞有升高趋势(P=0.0830)。
  • 接种后记忆B细胞和浆母细胞比例无显著变化。
  • pSS患者疫苗特异性IgG水平高于健康对照(P=0.001)。

关键数值与推荐

  • pSS患者接种后Tfh细胞变化P=0.1748,健康对照P=0.0005。
  • pSS患者接种后Th1和Th17细胞升高P<0.05,健康对照Th1趋势P=0.0830。
  • pSS患者疫苗特异性IgG高于健康对照P=0.001。

临床怎么用

  • 研究结果支持在pSS患者中应用流感疫苗,风湿免疫科医生可据此向患者推荐接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Influenza vaccination is effective in preventing infections in most people. This study aimed to assess the changes of immune responses in primary Sjögren's Syndrome (pSS) patients after influenza vaccination and determine the safety of influenza vaccination. METHODS: A total of 17 patients with pSS and 16 healthy controls (HCs) were included. Peripheral mononuclear cells were analysed by flow cytometry. Vaccine-specific antibodies were determined by ELISA. Clinical features and serological responses were monitored. RESULTS: The percentages of T follicular helper cell (Tfh) were significantly elevated in HCs after vaccination (P=0.0005), while no significant differences in the levels of Tfh in pSS patients were identified (P=0.1748). The proportions of Th2 cells were significantly decreased after vaccination in both pSS patients and HCs (P<0.05). In contrast, the percentages of Th1 cells and Th17 cells were significantly increased after vaccination in pSS patients (P<0.05), while no significant differences in the percentages of Th1 and Th17 cells were identified in HCs (P>0.05), although a trend towards higher levels of Th1 cells was observed (P=0.0830). No significant changes in the proportions of memory B cells and plasmablasts were observed after vaccination. Patients with pSS developed higher levels of vaccine-specific IgGs compared with HCs (P=0.001). No significant changes in disease manifestations and laboratory parameters were observed after vaccination. No increased vaccination related adverse effect was observed in pSS. CONCLUSION: Our findings suggest the feasibility of applying influenza vaccines to patients with pSS, raising awareness for vaccination among the rheumatology community and involved healthcare professionals.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zhou X, Liu Y, Jin Y, et al. Immune responses after influenza vaccination in patients of primary Sjögren's syndrome. Rheumatology (Oxford). 2021. PMID: 32671409. doi:10.1093/rheumatology/keaa243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。